Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Breast 2Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 10Kidney Neoplasms 2Carcinoma, Renal Cell 2Ovarian Neoplasms 1Inflammation 1Endometriosis 1Cardiovascular Diseases 1Breast Neoplasms 1Advanced Renal Cell Carcinoma (RCC) 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Atorvastatin × Genitourinary × Clear all
NCT05796973 2025-06-27

MOVES

Tampere University Hospital

Phase 3 Recruiting
240 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡